224 related articles for article (PubMed ID: 21778901)
21. Clinical images: Dialysis-associated uremic tumoral calcinosis.
Oglesby R; Ceruti R; De Luigi J; Cueto P
Arthritis Rheum; 2002 May; 46(5):1416. PubMed ID: 12115262
[No Abstract] [Full Text] [Related]
22. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
Lammoglia JJ; Mericq V
Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
[TBL] [Abstract][Full Text] [Related]
23. Tumoral calcinosis in patients on hemodialysis. Case report and review of the literature.
Pecovnik-Balon B; Kramberger S
Am J Nephrol; 1997; 17(1):93-5. PubMed ID: 9057960
[TBL] [Abstract][Full Text] [Related]
24. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
St Peter WL; Liu J; Weinhandl E; Fan Q
Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
26. Uremic tumoral calcinosis in patients on peritoneal dialysis: clinical, radiologic, and laboratory features.
Chu HY; Chu P; Lin YF; Chou HK; Lin SH
Perit Dial Int; 2011; 31(4):430-9. PubMed ID: 21357938
[TBL] [Abstract][Full Text] [Related]
27. Giant calcified mass in a hemodialysis patient.
Combalia A; Munoz-Mahamud E; Cofan F
Kidney Int; 2019 Mar; 95(3):719. PubMed ID: 30784665
[No Abstract] [Full Text] [Related]
28. Resolution of uremic tumoral calcinosis in a patient on peritoneal dialysis with long-term low-calcium dialysate treatment.
Kim Y; Hwang E; Park S
Kidney Res Clin Pract; 2014 Dec; 33(4):226-8. PubMed ID: 26885482
[TBL] [Abstract][Full Text] [Related]
29. [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Bellotti G; Presta P; Panzino T; Capria M; Caglioti A; Riccio M; Bova F; Fuiano L; Fuiano G
G Ital Nefrol; 2009; 26(3):372-6. PubMed ID: 19554535
[TBL] [Abstract][Full Text] [Related]
30. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
31. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
32. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
Russo D; Miranda I; Ruocco C; Battaglia Y; Buonanno E; Manzi S; Russo L; Scafarto A; Andreucci VE
Kidney Int; 2007 Nov; 72(10):1255-61. PubMed ID: 17805238
[TBL] [Abstract][Full Text] [Related]
33. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
Marangon N; Lindholm B; Stenvinkel P
Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe metastatic calcification in hemodialysis patients.
Yeh SM; Hwang SJ; Chen HC
Hemodial Int; 2009 Apr; 13(2):163-7. PubMed ID: 19432688
[TBL] [Abstract][Full Text] [Related]
35. [Improvement of tumoral calcinosis of the right hand after parathyroidectomy in a patient on chronic hemodialysis].
El Maghraoui J; Hammou M; Kabbali N; Arrayhani M; Houssaini TS
Pan Afr Med J; 2016; 24():30. PubMed ID: 27583094
[TBL] [Abstract][Full Text] [Related]
36. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
37. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice.
Winkelmayer WC; Tonelli M
Am J Kidney Dis; 2008 Mar; 51(3):362-5. PubMed ID: 18295050
[No Abstract] [Full Text] [Related]
38. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
39. Amelioration of uremic tumoral calcinosis with high-flux hemodialysis treatment.
Xie T; Zhang Y; Tang X; Chen M; Zhang W
Int Urol Nephrol; 2014 Jul; 46(7):1467-8. PubMed ID: 24595601
[No Abstract] [Full Text] [Related]
40. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
Assimon MM; Mousa S; Shaker O; Pai AB
Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
